# Mablink Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mablink-bioscience-s-a-s

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.mablink.com
- Total disclosed funding: $35M
- Latest round: Series A (Sep 29, 2022)
- Investors on record: 9

## About

Based in Lyon, France and founded in 2018, Mablink Bioscience S.A.S. operates as a biotechnology company that focuses on developing drug therapies for cancer. The company was founded by CEO Jean-Guillaume Lafay and CSO Warren Viricel. In April 2021, Mablink Bioscience raised EUR 4 million (USD 4.83 million) in Seed funding from Elaia Partners, Groupe Crédit Agricole, and Simba Santé.

Mablink Bioscience provides PSARlink™ is the company’s patented ADC platform that focuses on hydrophilic drug-linker and improvement of pharmacological properties.

The company plans to use its proceeds from seed funding to move forward with its ADC (Antibody-Drug Conjugates) pipeline.

## Funding rounds

- Series A, Sep 29, 2022, $30M — Sofinnova Partners, Elaia Partners, UI Investissement, Groupe Crédit Agricole, Merieux Equity Partners, Sham Innovation Santé, Simba Santé, Fournier-Majoie Foundation
- Seed, Jun 17, 2021, $4.8M — Elaia Partners, Groupe Crédit Agricole, Pertinence Invest, Sham Innovation Santé, Simba Santé, Fournier-Majoie Foundation

## Investors

- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Seed, Series A
- Groupe Crédit Agricole — Seed, Series A
- Pertinence Invest — Seed
- Sham Innovation Santé — Seed, Series A
- Simba Santé — Seed, Series A
- Fournier-Majoie Foundation (https://capitalatlas.ai/funds/fournier-majoie-foundation) — Seed, Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series A
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series A